Zegerid

Zollinger-Ellison Syndrome, Curling Ulcer, Heartburn + 15 more
Treatment
15 FDA approvals
20 Active Studies for Zegerid

What is Zegerid

OmeprazoleThe Generic name of this drug
Treatment SummaryMagnesium hydroxide is a naturally occurring mineral that is used in a variety of ways. It can be taken orally as a liquid suspension or chewable tablet to act as an antacid or laxative. It is also used commercially as a fire retardant due to its smoke suppressing and flame retardant properties. Magnesium hydroxide can also be applied directly to the skin to act as a deodorant or to treat canker sores.
Prilosecis the brand name
image of different drug pills on a surface
Zegerid Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Prilosec
Omeprazole
1990
669

Approved as Treatment by the FDA

Omeprazole, otherwise called Prilosec, is approved by the FDA for 15 uses which include Gastro-esophageal Reflux Disease (GERD) and multiple endocrine adenomas .
Gastro-esophageal Reflux Disease (GERD)
multiple endocrine adenomas
Gastric Ulcer
Gastroesophageal Reflux
Healing
Zollinger-Ellison Syndrome
Helps manage Zollinger-Ellison Syndrome
Heartburn
Helps manage Heartburn
Stomach Ulcer
Duodenal Ulcer
Helicobacter Pylori Infection
Used to treat Helicobacter Pylori Infection in combination with Amoxicillin
Heartburn
Helps manage Heartburn
Heartburn
Erosive Esophagitis
Adenoma
Curling Ulcer

Effectiveness

How Zegerid Affects PatientsMagnesium hydroxide is an antacid, meaning it reduces stomach acid by reacting with hydrochloric acid in the stomach. This reaction forms magnesium chloride and water, which helps to reduce irritation in the stomach, raise the pH level, and stop pepsin from working. Magnesium hydroxide also strengthens the barrier between the stomach and esophagus, as well as improving the strength of the muscles that control the stomach and esophagus. As a laxative, magnesium hydroxide increases the amount of water in the intestines, causing the colon to expand and leading to increased movement in the digestive system and eventually evacuation of
How Zegerid works in the bodyMagnesium hydroxide helps to neutralize stomach acid when taken in small doses. If taken in larger doses, it acts as a laxative. The magnesium hydroxide combines with stomach acid to form magnesium chloride and water, which helps to reduce stomach acidity. When taken in larger doses, it can draw water into the intestines, softening stools and increasing intestinal motility, which stimulates the urge to have a bowel movement. Magnesium hydroxide can also release a hormone called cholecystokinin, which helps the intestines absorb more water and electrolytes.

When to interrupt dosage

The degree of Zegerid is contingent upon the determined diagnosis, including Acid indigestion, Upset stomach and Antacid therapy. The quantity of dosage is dependent upon the mode of administration stated in the table below.
Condition
Dosage
Administration
hypersecretory conditions
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Heartburn
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Gastroesophageal Reflux
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Heartburn
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Prophylaxis of NSAID gastric ulceration
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Rheumatoid Arthritis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Ankylosing Spondylitis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Mastocytosis, Systemic
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Stomach Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Helicobacter Pylori Infection
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Osteoarthritis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Zollinger-Ellison Syndrome
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Curling Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Adenoma
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Erosive Esophagitis
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Stomach Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Healing
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release
Peptic Ulcer
40.0 mg, , 10.0 mg, 20.0 mg, 20.6 mg, 2.5 mg
Oral, Capsule, delayed release pellets - Oral, , Capsule, delayed release - Oral, Capsule, delayed release, Tablet, delayed release - Oral, Tablet, delayed release, Capsule, Capsule - Oral, Capsule, delayed release pellets, Kit, Powder, for suspension - Oral, Powder, for suspension, Granule, delayed release, Granule, delayed release - Oral, Capsule, gelatin coated, Tablet, film coated, Tablet, film coated - Oral, Tablet, Delayed Release - Oral, Capsule, gelatin coated - Oral, Tablet, orally disintegrating, delayed release - Oral, Tablet, chewable, Tablet, chewable - Oral, Tablet - Oral, Tablet, Kit - Oral, For suspension - Oral, For suspension, Tablet, Delayed Release, Tablet, orally disintegrating, delayed release

Warnings

Zegerid Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Omeprazole may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Omeprazole may interact with Pulse Frequency
There are 20 known major drug interactions with Zegerid.
Common Zegerid Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Omeprazole.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Omeprazole.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Omeprazole.
Aminophylline
Major
The metabolism of Aminophylline can be increased when combined with Omeprazole.
Amoxapine
Major
The metabolism of Amoxapine can be decreased when combined with Omeprazole.
Zegerid Toxicity & Overdose RiskThe toxic dose of magnesium hydroxide in rats is 8500mg/kg. Common side effects include drowsiness and feeling flushed. If taken daily, it can cause changes in fluid and electrolyte levels. Taking too much may cause abdominal cramping, nausea, and/or diarrhea. Symptoms of overdose include gastrointestinal irritation, watery diarrhea, nausea, vomiting, feeling flushed, thirst, low blood pressure, confusion, weak muscles, slowed breathing, irregular heartbeat, coma, and cardiac arrest. It should not be used if someone has kidney disease or a magnesium restricted diet, sudden changes in bowel movements lasting over two weeks, abdominal pain
image of a doctor in a lab doing drug, clinical research

Zegerid Novel Uses: Which Conditions Have a Clinical Trial Featuring Zegerid?

Presently, 43 active studies are assessing the potential of Zegerid to attenuate Gastric Acid Suppression, Flatulence and Acid Indigestion.
Condition
Clinical Trials
Trial Phases
Rheumatoid Arthritis
56 Actively Recruiting
Not Applicable, Phase 4, Phase 3, Phase 2, Phase 1
Heartburn
12 Actively Recruiting
Phase 3, Phase 2, Not Applicable
Gastroesophageal Reflux
0 Actively Recruiting
Prophylaxis of NSAID gastric ulceration
0 Actively Recruiting
Mastocytosis, Systemic
0 Actively Recruiting
hypersecretory conditions
0 Actively Recruiting
Stomach Ulcer
2 Actively Recruiting
Phase 4, Not Applicable
Erosive Esophagitis
2 Actively Recruiting
Phase 2, Phase 3
Helicobacter Pylori Infection
2 Actively Recruiting
Not Applicable, Phase 4
Ankylosing Spondylitis
3 Actively Recruiting
Phase 3, Not Applicable
Stomach Ulcer
0 Actively Recruiting
Heartburn
2 Actively Recruiting
Phase 3, Not Applicable
Zollinger-Ellison Syndrome
0 Actively Recruiting
Osteoarthritis
0 Actively Recruiting
Curling Ulcer
0 Actively Recruiting
Peptic Ulcer
0 Actively Recruiting
Adenoma
0 Actively Recruiting
Healing
0 Actively Recruiting

Zegerid Reviews: What are patients saying about Zegerid?

5Patient Review
7/31/2012
Zegerid for Medication Treatment for Healing Erosive Esophagitis
I experienced some drowsiness while taking this medication, which was alleviated by running in the mornings. Otherwise, it did a great job at relieving my sensitive stomach and food allergies.
5Patient Review
2/2/2012
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This treatment has been extremely effective for me, though I have experienced some negative side effects like swollen ankles due to the high sodium content.
5Patient Review
7/2/2011
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
My Gastro had me on every prescribe medication. Then He decided to try this. As I as well had surgery to try and control the acid reflux problem, which did help) But Zegerid in the powder form worked best for me. Some side effects but it is worth it. This is the FIRST time I have remarked on any medication.But again for what ever reason the pills where not effctive as well as the powder form for me. And it is instant relief within mins.
5Patient Review
11/1/2011
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This didn't work for me, unfortunately.
5Patient Review
12/27/2011
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This medication has done wonders for my son who suffers from GERD. He used to be in a lot of pain, and would even choke sometimes. Now he's practically symptom-free and it's made such a difference in his quality of life.
5Patient Review
12/26/2013
Zegerid for Conditions of Excess Stomach Acid Secretion
I was struggling with GERDs and tried a bunch of different meds that didn't help at all. A friend recommended this one, and I'm so glad they did! It's by far the best medication I've tried—I don't even get breakthrough symptoms anymore.
5Patient Review
7/25/2015
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
I cannot stress enough how much this has helped me. I was struggling with gastroparesis and GERD for years, and nothing the doctors gave me ever worked. But Zegerid? Zegerid is a life saver.
5Patient Review
4/12/2014
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This is the only medication that works for my GERD. No side effects to speak of. Slightly pricey...but so is an ER visit.
5Patient Review
5/12/2016
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
I've been taking Zegrid for a long time to manage my stomach acid. I've tried other proton pump inhibitors, but I always come back to this one because it's the most effective.
5Patient Review
11/28/2015
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This treatment is really effective. I've tried other things like Prilosec, but this is by far the best.
4.7Patient Review
5/24/2011
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
4.7Patient Review
4/20/2012
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
Zegrid has been an absolute lifesaver for me. I can now eat and drink things that were previously off limits due to my acid reflux. It's amazing how much this medication has improved my quality of life.
3Patient Review
9/23/2013
Zegerid for Conditions of Excess Stomach Acid Secretion
I'm really surprised at how quickly Zegerid worked.
2.7Patient Review
8/24/2011
Zegerid for Condition in which Stomach Acid is Pushed Into the Esophagus
This provided some relief, which was good.
2.3Patient Review
10/16/2011
Zegerid for Conditions of Excess Stomach Acid Secretion
After taking Zegrid for two days, I started feeling awful. I had fatigue, body aches, headaches, and nausea. So, I stopped taking it.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about zegerid

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the difference between Zegerid and Prilosec?

"Both Zegerid and Prilosec contain PPIs, but Zegerid also has an antacid. You can get Prilosec OTC or as a generic, and side effects for both drugs can include headache, stomach/abdominal pain, nausea, gas, and diarrhea."

Answered by AI

Which is better Nexium or Zegerid?

"Nexium works to relieve heartburn better than other antacids, but there are some risks associated with long-term use. Most people can take Zegerid without any noticeable side effects. Zegerid lasts longer than other types of antacids, so you may only need to take it once a day."

Answered by AI

What is Zegerid used for?

"Zegerid OTC is a heartburn medication that contains the proton pump inhibitor omeprazole. It is used to treat frequent heartburn, which is defined as heartburn occurring two or more days per week. Omeprazole works by reducing acid production, which relieves heartburn symptoms."

Answered by AI

Is Zegerid the same as Zantac?

"Zegerid and Zantac are both used to treat stomach problems, but they work in different ways. Zegerid is a combination of a proton-pump inhibitor (PPI) and an antacid, while Zantac is an H2 (histamine-2) receptor blocker. Both drugs can cause side effects such as headache, stomach or abdominal pain, nausea, and diarrhea."

Answered by AI

Clinical Trials for Zegerid

Image of Sunnybrook Health Sciences Centre in Toronto, Canada.

Steroids for Rheumatoid Arthritis

18+
All Sexes
Toronto, Canada
People living with rheumatoid arthritis (RA) often experience flares-periods where their symptoms suddenly get worse. These flares can cause significant pain, make it harder to move and do daily activities, and lower overall quality of life. Doctors often treat flares with medications called glucocorticoids (GCs), which reduce inflammation. These medications can be taken by mouth (oral/PO) or given as a single injection into the muscle (intramuscular/IM). However, it's not clear which option works better from the patient's point of view-especially when it comes to relief of symptoms, improvements in function, and satisfaction with treatment. Most research so far has focused on how well the drugs control the disease, rather than how they impact the patient's overall experience. Research Questions: 1. Does a single GC injection work just as well as taking pills over a few weeks in improving symptoms reported by patients? 2. How do the two treatments compare in terms of symptom relief, ability to function, and patient satisfaction? 3. What do patients think and feel about using GCs to treat RA flares? What the Investigators Think: The investigators believe that a one-time GC injection is just as good as taking pills for a few weeks when it comes to managing RA flares. In fact, the injection might even be safer and preferred by patients. What the Investigators are Doing: The investigators will study 220 adults with RA who are currently having a flare (with at least 3 swollen and tender joints). These patients will be recruited from rheumatology clinics at the University of Toronto and must not have used GCs in the past month. They will be randomly assigned to receive either: A single injection (Methylprednisolone 120 mg), or Oral pills (Prednisone starting at 15 mg daily and tapering down over 3 weeks). The main thing the investigators will look at is how much better patients feel after 6 weeks, based on a questionnaire designed to measure RA flares. The investigators will also look at how well they function, how satisfied they are with the treatment, and whether they had any side effects. In addition, 20 patients (10 from each group) will be interviewed to understand their experiences and opinions about flare treatment in more detail. Why This Is Possible: The investigators have already surveyed University of Toronto rheumatologists who support the idea and provided input on study design. The investigators have also partnered with experts in research methods, national arthritis organizations, and patient groups to make sure the study is relevant and meaningful. Ethics approval has been obtained. Why It Matters: RA flares can have a major impact on people's lives. While current treatments help control inflammation, the investigators need to better understand how these treatments affect people from their own perspective. This study will shift the focus to what matters most to patients, helping doctors and patients choose the best treatment based not only on medical results but also on the patient's experience. This could lead to more effective and personalized care for people living with RA.
Phase 4
Waitlist Available
Sunnybrook Health Sciences Centre (+4 Sites)
Image of California Clinical Trials Medical Group in Glendale, United States.

NTR-1011 for Lupus and Rheumatoid Arthritis

18 - 75
All Sexes
Glendale, CA
This phase 1a and 1b study is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and preliminary efficacy of NTR-1011 in healthy adults and in adult patients with systemic lupus erythematosus and rheumatoid arthritis. The main goals of this study are to determine the safety profile of NTR-1011 across subcutaneous and intravenous dose levels, understand how the drug behaves in the body, characterize its biological activity through relevant pharmacodynamic markers, assess the potential for immune responses to treatment, and explore early signals of clinical benefit in autoimmune disease settings. This is a randomized, double blind, placebo controlled study that begins with a single ascending dose evaluation in healthy volunteers followed by a multiple dose assessment in patients. The design is intended to define the highest safe and well tolerated dose, establish a robust PK and PD baseline, and generate initial patient level evidence to support dose selection and advancement into subsequent clinical development.
Phase 1
Recruiting
California Clinical Trials Medical GroupHakop Gevorkyan, MDNeutrolis
Have you considered Zegerid clinical trials? We made a collection of clinical trials featuring Zegerid, we think they might fit your search criteria.Go to Trials
Image of Weill Cornell Medical College in New York, United States.

Health Coaching for Rheumatoid Arthritis

18+
All Sexes
New York, NY
The goal of this clinical trial is to learn if peer coaching works to reduce levels of anxiety and/or depression in adults diagnosed with Rheumatoid Arthritis (RA). The main questions it aims to answer are: Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months from baseline? Do people with RA who complete the intervention with a peer coach have lower levels of anxiety and/or depression at 6 months compared to those in the control arm? Researchers will compare the peer coaching intervention to an active-control arm (where people without RA coach participants on general health and nutrition topics) to see if peer coaching works to reduce anxiety and/or depression. Participants will meet with a coach every week for 9 weeks and complete several surveys before, during and after the intervention
Recruiting
Has No Placebo
Weill Cornell Medical CollegeIris Y Navarro-Millán, MDBristol-Myers Squibb
Image of Humana Healthcare Research, Inc. in Louisville, United States.

Academic Detailing for Rheumatoid Arthritis

Any Age
All Sexes
Louisville, KY
The goal of this trial is to learn if an interactive evidence-based educational outreach visits to clinicians who prescribe biologics change prescribing of biosimilar medications. The main questions it aims to answer are: 1. Do educational outreach visits lead to a higher number of prescriptions for biosimilar versions of adalimumab? 2. Do in-person or virtual visits work better? Researchers will compare clinicians offered the educational outreach visit to those who are not offered the visit to see if there is a difference in prescribing of biosimilar versions of adalimumab instead of the original brand-name version. Participants will be offered the chance to meet with a trained clinician who will provide educational information tailored to their knowledge and attitudes on the topic. They will also be provided an educational brochure and patient educational materials.
Waitlist Available
Has No Placebo
Humana Healthcare Research, Inc. (+1 Sites)
Image of Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016) in New York, United States.

Electromagnetic Resonance Therapy for Autoimmune Diseases

Any Age
All Sexes
New York, NY
The ImmuneNet study is a Phase I/II clinical trial sponsored by Truway Health, Inc. It will test whether gentle, low-frequency electromagnetic resonance (LF-EMR) can influence how immune cells communicate and synchronize with each other. The goal is to see if this "quantum-synaptic" signaling effect can help stabilize immune activity and reduce the number of autoimmune flare-ups in people living with conditions such as lupus, rheumatoid arthritis, or multiple sclerosis. Participants will receive either an active or a sham (placebo) LF-EMR session three times per week for twelve weeks. Each session is completely non-invasive. Blood samples will be collected to study cytokines (immune-system messenger molecules), gene-expression patterns, and electrical field coherence among immune cells. A machine-learning system will analyze these data to predict inflammation patterns and guide individualized treatment settings. All participant data will be securely recorded and time-stamped to ensure transparency and privacy. The expected outcome of the study is a measurable reduction in autoimmune flare frequency and symptom severity, along with improved understanding of how electromagnetic signaling might safely regulate immune function.
Phase 1 & 2
Waitlist Available
Truway Health, Inc. www.truwayhealth.com (401 E 34th Street, S11P, New York, NY 10016)Gavin Solomon, President & CEOTruway Health, Inc.
Have you considered Zegerid clinical trials? We made a collection of clinical trials featuring Zegerid, we think they might fit your search criteria.Go to Trials
Image of University of Minnesota Medical School, Division of Rheumatic and Autoimmune Diseases in Minneapolis, United States.

Ultrasound Therapy for Rheumatoid Arthritis

18+
All Sexes
Minneapolis, MN
The At-Home ULTRA Study will evaluate performance of the MINI system as indicated for the treatment of adults with active, moderate to severe rheumatoid arthritis who are inadequate responders or are intolerant to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs), biologic DMARDs (bDMARDs), or targeted synthetic DMARDs (tsDMARDs). The non-invasive study device delivers ultrasound stimulation to the spleen to reduce inflammation. The study will enroll at least 60 participants at up to 8 sites. There will be three arms consisting of two active stimulation groups (treatment) and one non-active stimulation group (sham-control). After completing the double-blinded primary endpoint assessment period at Week 12, there will be a one-way crossover of control participants to active stimulation and an additional 12 week follow-up with all participants to evaluate long-term outcomes.
Recruiting
Drug
University of Minnesota Medical School, Division of Rheumatic and Autoimmune DiseasesDaniel ZachsSecondWave Systems Inc.
Image of Del Sol Research Management, LLC in Tucson, United States.

Linaprazan Glurate vs Lansoprazole for Acid Reflux

18 - 80
All Sexes
Tucson, AZ
The goal of this clinical trial is to find out how well linaprazan glurate can heal erosive esophagitis (EE) caused by gastroesophageal reflux disease (GERD), compared to lansoprazole, a commonly used medication. Researchers will also evaluate whether linaprazan glurate: * Reduces heartburn symptoms more effectively than lansoprazole * Is safe and well tolerated, based on physical exams, blood tests, and vital signs (heart rate, blood pressure, temperature, and breathing rate) * Causes any side effects during treatment * Has different effects depending on how much of the drug is in the blood * Works differently depending on participants' genes Participants must be between 18 to 80 years old and have EE due to GERD confirmed by an endoscopy. Participants cannot join if they have an active Helicobacter pylori (HP) infection or were treated for HP in the past 6 weeks or have taken antibiotics or bismuth-containing drugs in the past 6 weeks. The study is a randomized, double-blind, active comparator-controlled trial lasting up to 4 months. Randomized means that participants are assigned by chance (like flipping a coin) to one of the treatment groups and double-blind means neither the participants nor the study team will know which treatment is given. Participants will be placed into one of three groups (about 167 people in each group): * Linaprazan glurate 50 mg twice a day * Linaprazan glurate 50 mg once a day * Lansoprazole 30 mg once a day Everyone will take 2 tablets and 1 capsule by mouth daily for 8 weeks. Some tablets or capsules will be placebos (look like medicine but contain no active drug). Participants will: * Undergo an endoscopy in the beginning and after 4 weeks of treatment * If healing is not observed, another endoscopy may be done at 8 weeks * During the procedure, doctors will use a thin, flexible tube with a camera to look at the esophagus and take small tissue samples (biopsies) * Have blood and urine tests at clinic visits to check overall health * Receive electrocardiograms (ECGs) to monitor heart function * Complete daily questionnaires on an electronic device about symptoms and experiences
Phase 3
Waitlist Available
Del Sol Research Management, LLC (+24 Sites)Cinclus Pharma Holding AB
Have you considered Zegerid clinical trials? We made a collection of clinical trials featuring Zegerid, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security